Economic evaluation of the PAX-D study

The PAX-D study is a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression. The Department of Health Economics is responsible for the main health economic analysis, which will include:

(i) a detailed patient-level cost analysis of health, social care and other broader societal costs for both the pramipexole and placebo arms of the trial and

(ii) an incremental within-trial economic evaluation comparing the pramipexole and placebo arms of the trial in terms of their costs and outcomes over the 48 week trial follow-up period.

Beside the traditional cost-utility analysis based on EQ-5D-5L data, the analysis will also include the assessment of outcomes from the perspective of the capability approach, based on information elicited with the OxCAP-MH and ICECAP-A instruments.

Dates: October 2019 – September 2022 (TBC)

Funding: National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation Programme, UK

Collaborator(s): Department of Psychiatry, University of Oxford

Information: Judit Simon, Timea Helter